Document Detail

The CAIRP (CAndesartan for In-stent Restenosis Prevention) Trial--a multicenter study of AT1-receptor blocker therapy in coronary stenting.
MedLine Citation:
PMID:  18460701     Owner:  NLM     Status:  MEDLINE    
Angiotensin II (Ang II) is implicated in the development of in-stent restenosis (ISR). Ang II- and AT1-receptor blockade could possibly reduce ISR. We enrolled 206 patients into a prospective double-blind, placebo-controlled, multicenter randomized trial of candesartan cilexitil 16 mg to test this notion. Mean lumen diameter (MLD) was the primary objective measured by quantitative coronary angiography and intravascular ultrasound. The Candesartan Group showed a trend towards a larger MLD at follow up without significant differences in the binary ISR rate. In vessels < 2.75 mm, we found a larger MLD in the treatment group after 6 months. This might indicate the potential benefit of AT1-receptor blocker therapy for certain subgroups when percutaneous coronary intervention is performed with bare-metal stent implantation.
Jochen Krämer; Rainer G Ruf; Sibylle Schmidt; Christoph Axthelm; Ruth Strasser; Gerhard Janssen; Torsten Thieme; Angelika Kusch; Jürgen Waigand; Rainer Dietz; C Michael Gross
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of invasive cardiology     Volume:  20     ISSN:  1557-2501     ISO Abbreviation:  J Invasive Cardiol     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-05-07     Completed Date:  2008-07-15     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  8917477     Medline TA:  J Invasive Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  205-10     Citation Subset:  IM    
Franz-Volhard-Klinik, Dept. for Molecular and Clinical Cardiology, HELIOS Klinikum Berlin, Charité, CBB, Wiltbergstrasse 50, 13125 Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Benzimidazoles / therapeutic use*
Blood Vessel Prosthesis Implantation*
Combined Modality Therapy
Coronary Angiography
Coronary Restenosis / drug therapy,  prevention & control*,  surgery
Double-Blind Method
Drug-Eluting Stents*
Middle Aged
Prospective Studies
Tetrazoles / therapeutic use*
Treatment Outcome
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Placebos; 0/Tetrazoles; S8Q36MD2XX/candesartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Predictors of difficult carotid stenting as determined by aortic arch angiography.
Next Document:  Invasive measurements of atrioventricular conduction parameters prior to and following ventricular s...